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OBJECTIVES To determine whether dobutamine stimulation in patients with Chagas’ disease may uncover
abnormal contractile responses as seen in ischemic myocardium.
BACKGROUND Segmental left ventricular (LV) dysfunction in the absence of coronary atherosclerosis is
frequently seen in patients with chronic Chagas’ heart disease. Myocardial ischemia and
coronary microcirculation abnormalities have been found in animal models and in humans
with Chagas’ disease. In addition, chagasic sera may contain autoantibodies against human
beta-adrenergic receptors.
METHODS Two groups of patients with Chagas’ disease were studied by echocardiography: group 1 (n 5
12) without and group 2 (n 5 14) with LV segmental wall motion abnormalities (mostly
apical aneurysm). Ten normal subjects served as control subjects. We performed qualitative
assessment of wall motion and quantitative evaluation of LV cavity under baseline conditions
and after dobutamine stimulation.
RESULTS Patients with Chagas’ disease exhibited a blunted inotropic and chronotropic response to
dobutamine stimulation. After dobutamine, fractional area change in Chagas’ group 1
(54.7 6 6.6%; SD) and in group 2 (35.1 6 12.1%) were significantly lower than control group
(66.7 6 2.5%; p , 0.001). In addition, in 6 of 14 group 2 patients, dobutamine induced a
biphasic response with improvement at low dose and deterioration at peak dose, as seen in
patients with coronary artery disease. Although the three groups had similar basal mean heart
rates and attained a similar mean peak dobutamine doses, both groups of patients with
Chagas’ disease had a significantly blunted mean heart rate effect after dobutamine (p ,
0.0001).
CONCLUSIONS Thus, dobutamine stimulation unmasks a chronotropic incompetence and a blunted myo-
cardial contractile response in chagasic patients, even in those with no overt manifestation of
heart disease. (J Am Coll Cardiol 1999;33:522–9) © 1999 by the American College of
Cardiology
About 16 to 18 million individuals in Latin America (1) are
thought to have chronic Chagas’ disease (positive serologic
test result) of whom 25% manifest cardiac involvement (2).
Approximately half of the patients with symptomatic Cha-
gas’ disease have a left ventricular (LV) apical aneurysm or
other segmental LV wall motion abnormalities, or both (in
particular of the posteroinferior wall) (3–5) whose origin is
poorly understood (6–8). Patients with Chagas’ disease
invariably exhibit normal angiographic appearance of the
coronary arteries (2–8). Recent experimental animal work
(6,9,10) and clinical studies (11) have demonstrated that
myocardial ischemia induced by abnormal coronary micro-
vasculature function may play an important role in the
pathophysiology of the disease, and we theorized that it
could impose a limitation in global contractile ventricular
reserve. In addition, sera of patients with Chagas’ disease
contain autoantibodies against both beta1 and beta2 adren-
ergic receptor subtypes with a theoretical gradual blockade
of myocardial neurotransmitter receptors impairing both
inotropic and chronotropic effects (12,13).
In parallel, developments in pharmacologic stress testing
have established dobutamine echocardiography as a useful
method to detect myocardial ischemia in patients exhibiting
limited coronary flow reserve typically due to obstructive
coronary artery disease (14,15). Dobutamine is primarily a
beta1 adrenoreceptor agonist with mild beta2 and alpha1
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adrenoreceptor stimulant activity. To our knowledge, the
clinical effect of dobutamine stimulation in chagasic patients
has not been described previously. Thus, this study was
designed to investigate whether dobutamine echocardiogra-
phy may uncover a limited contractile or impaired chrono-
tropic reserve in patients with chronic Chagas’ heart disease
based on the hypothesis of abnormal coronary microcircu-
lation (i.e., in the absence of epicardial coronary artery
disease) and myocardial adrenergic dysfunction.
METHODS
Study patients. We prospectively studied 28 consecutive
patients with chronic Chagas’ heart disease between Octo-
ber 1993 and February 1996, among 466 subjects referred to
the Echocardiography Laboratory of the Centro Me´dico
and Hospital Universitario de Caracas to undergo stress
echocardiography. Two patients were excluded for analysis,
one because of the presence of aortic stenosis and another
because of chronic atrial fibrillation. In the remaining 26
patients, the clinical presentation included palpitations in 8,
transient cerebrovascular embolic episodes in 3, atypical
chest pain in 3, and 1 had an episode of congestive heart
failure. The diagnosis of Chagas’ disease was based on
epidemiology, positive serologic findings by two tests and
characteristic electrocardiographic and/or clinical findings
(4). Ten other Chagas’ seronegative subjects who were
found to have a normal dobutamine test result, five of whom
underwent coronary angiography that was normal, consti-
tuted the control group. All patients and subjects underwent
a complete physical examination, electrocardiogram (ECG),
chest X-rays, serum sampling, two-dimensional and Dopp-
ler echocardiographic study. None had evidence of heart
failure on physical or radiologic examination. We excluded
patients with unstable angina or myocardial infarction,
history of ventricular tachycardia or fibrillation, sick sinus
syndrome, complete heart block, valvular heart disease,
obstructive lung disease, arterial hypertension, diabetes mel-
litus, pregnancy, alcoholism or subjects with an age of ,18
or .70 years. The study protocol was approved by the
Ethics Committee of Centro Me´dico de Caracas. Informed
consent was obtained in all subjects.
The Chagas’ patient population (n 5 26) was classified
according to the presence of normal (group 1, n 5 12) or
abnormal (group 2, n 5 14) wall motion on the baseline
echocardiogram. Coronary arteriography was normal in all
patients in whom it was performed (n 5 10) among those in
group 2. Three of these patients refused to undergo cardiac
catheterization and one patient died before angiography
could be performed. We did not obtain coronary angiogra-
phy in group 1 subjects (without wall motion abnormali-
ties). Within group 2 patients, six were being treated with
either enalapril or captopril, two each were receiving low
dose amiodarone or digoxin and one each was receiving
warfarin or long-term aspirin therapy. No patients were
receiving beta-adrenergic blockers or calcium antagonists.
Eighteen patients were receiving no treatment.
Study protocol. Dobutamine stress echocardiography was
carried out via a standard protocol (15) starting with a dose
of 5 mg/kg per minute administered IV, increased every
3 min to 10, 20, 30, and 40 (in control subjects), up to
50 mg/kg per minute in the patient groups. No patient
received atropine. Heart rate (HR), blood pressure, arrhyth-
mias and ECG changes were monitored. The standard
parasternal long- and short-axis views and apical four- and
two-chamber LV apical views were obtained with a 2.5-
MHz transducer with the patient lying in a left lateral
decubitus position. Images were recorded on VHS 0.5-in.
videotape during the last minute of every dose. An echo-
cardiographic system (Hewlett-Packard Sonos 1500 or
2500) was employed. Analysis of myocardial response was
performed from selected LV images digitized and stored in
cine-loop format or in optical disk. The selected images
were acquired at end-exhalation to minimize respiratory
interference. The test was stopped if the patient developed
ventricular or atrial tachycardia, hypotension (,90 mm Hg)
or hypertension (systolic $200 mm Hg) angina, achieve-
ment of 85% of the maximal predicted HR, a maximum
dobutamine dose of $40 mg/kg per minute, and/or devel-
opment or worsening in wall motion abnormality. After the
conclusion of the study, patients were monitored for 10
more minutes. Image acquisition in all patients and subjects
was performed by the same cardiac sonographer.
Qualitative analysis of LV systolic wall motion. We
employed the LV wall motion model of 16 segment
proposed by the American Society of Echocardiography
(16). Each segment was evaluated by two independent
observers employing the following scoring system: 1 for
normal, 2 for hypokinetic, 3 for akinetic and 4 for dyskinetic
(or aneurysm). Hyperdynamic LV wall motion obtained at
peak dobutamine dose was also scored as 1. The mean wall
motion score index was obtained by summing the grades of
each segment and dividing by the total number of segments
analyzed. An idealized normal dobutamine response score
index would be 1 at baseline and 1 at peak dose. Contractile
reserve was noted to be present both when hyperkinesis
developed as well as when a segment with baseline abnormal
wall motion improved resulting in a reduction in wall
motion score. Other types of contractile responses to do-
butamine infusion would be worsening in segmental LV
function resulting in an increased score, as seen due to
myocardial ischemia and a biphasic response consisting of
Abbreviations and Acronyms
ECG 5 electrocardiogram or electrocardiographic
EDA 5 end-diastolic left ventricular cavity area
ESA 5 end-systolic left ventricular cavity area
HR 5 heart rate
LV 5 left ventricle or left ventricular
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improved segmental function at low dose dobutamine fol-
lowed by worsening at high dose as seen in hibernating
ischemic myocardium (17). The echocardiographic studies
and segmental responses were graded by three of us.
Disagreements were resolved by an observer (J.E.P.) un-
aware of the patients’ clinical history or findings.
Quantitative analysis of LV cavity areas. Quantitative
analysis of the LV cavity areas was carried out from the
two-chamber apical view at end diastole (EDA) and at end
systole (ESA) (both at baseline and at peak dobutamine
dose). We have described previously that the apical aneu-
rysm involvement in most patients with Chagas’ heart
disease is more extensively displayed employing this view
(4). In the four-chamber apical view, the systolic motion of
the Chagasic aneurysm tends to be, in some patients,
off-line from the LV long axis resulting in apical tangential
views.
LV echocardiographic images depicting distinct endocar-
dial definition were digitized (ECG-R wave triggered, 60
frames, 30-ms interval) using a cine-loop dual split-screen
format to measure end diastole and end systole. All cavity
area measurements were performed by careful advancing of
the digital images frame by frame. End diastole was defined
as the frame at the peak of the ECG R wave or the frame
displaying maximal cavity area. End systole was defined as
the frame immediately before the opening of the mitral
valve leaflets. LV fractional area change (percent) was
obtained by the following: (EDA-ESA)/EDA 3 100. Only
supraventricular conducted beats were digitized for analysis.
In the case of premature ventricular contractions, the beat
immediately after the postextrasystolic beat was utilized for
measurements. Each LV cavity area measurement was
expressed as the mean value measured by two independent
observers (I.S., H.A.). Each beat was measured three or
more times by each observer. Interobserver variability for
the measurement of LV cavity areas in a given frame ranged
between 0.9% and 1.8% for end diastole and between 1.5%
and 1.6% for end systole.
Statistical analysis. Continuous variables were expressed
as mean 6 SD. Changes in HR, blood pressure, score
indexes, EDA, ESA, fractional area change, before and at
peak dobutamine doses were compared by two-way repeated
measures analysis of variance. Analysis of HR changes at
each increasing dobutamine dose had the dobutamine vari-
able nested by clinical group. Fisher exact test was per-
formed to compare categorical variables. Results of the
dobutamine test in predicting future cardiovascular events
were performed by Fisher exact test (Yates’ correction),
multiple regression analysis and by the Cox proportional
hazard rate method (STATISTICA v 4.5, StatSoft, Inc.,
Tulsa, Oklahoma). The null hypothesis was rejected at the
95% confidence level considering a p value ,0.05 as
significant.
RESULTS
Clinical data. There were no significant differences among
groups 1, 2 and control with respect to gender (p 5 0.40) or
mean age (p 5 0.16), although control subjects were
somewhat older than patients in both Chagas’ groups
(Table 1). All subjects from group 1 and one patient from
group 2 were asymptomatic. Within group 2, 10 of 14
patients were in class I and three patients were in class II
New York Heart Association functional status. Eleven of 12
patients from group 1 had normal ECGs, whereas in only 4
of 14 of group 2 subjects, the ECG was normal (p , 0.001).
Other significant ECG abnormalities included ST-T seg-
ment elevation on precordial leads present only in group 2
patients (p 5 0.003) and right bundle branch block (p 5
0.044) (Table 1).
Baseline echocardiography. By definition, all subjects
from Chagas’ group 1 had normal resting LV wall motion
pattern. The baseline echocardiographic LV segmental wall
motion abnormalities in group 2 patients included apical
aneurysm in 10 patients, apical akinesis in 3, akinesis or
hypokinesis of the posteroinferior wall in 9, akinesis or
Table 1. Clinical and Electrocardiographic Characteristics of Study Patients
Control Group
(n 5 10)
Chagas Group 1
(n 5 12)
Chagas Group 2
(n 5 14) p Value
Male/female 3/7 7/5 7/7 0.40
Age 6 SD, yr 56 6 9 45 6 6 50 6 11 0.16
ECG:
normal 10 11 4 , 0.001
ST-T 0 0 6 0.003
VPC 0 2 5 0.09
RBBB 0 1 5 0.044
LAFB 0 0 3 0.08
AV-1 0 0 2 0.19
Q 0 0 2 0.19
Group 2 patients also had one of each: transient idioventricular rhythm, frequent atrial extrasystoles or deep T-wave inversion
in precordial leads. ST-T 5 abnormal convex upwards ST-T segment elevation on percordial leads; VPC 5 ventricular
premature contractions; RBBB 5 right bundle branch block; LAFB 5 left anterior fascicular block; AV-1 5 first degree
atrioventricular block. For definition of groups see “Methods” section.
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hypokinesis of the posterior septum in 4 and 2 that
exhibited generalized hypokinesis. Three of 10 patients with
an apical wall motion abnormality had normal ECGs.
HR response and blood pressure during dobutamine
infusion. The mean peak dobutamine dose achieved for
the three patient groups was 38 6 10 mg/kg per minute. As
shown in Table 2, although the three patient groups had no
significant differences in mean HR at baseline (p 5 0.442)
and in the peak dobutamine dose attained (p 5 0.072),
there was a highly significant difference in the mean HR
reached at peak dobutamine dose (p , 0.0001). Although
the control group attained a maximum mean HR of 137 6
3 beats/min, both Chagas’ groups reached a significantly
lower mean peak HR; group 1 of 130 6 13 beats/min and
group 2 of 102 6 23 beats/min (p , 0.0003, each against
control). There were also significant differences in achieving
the age-corrected maximum predicted HR during stress
(p 5 0.002) (Table 2).
Analysis of the HR response to each dobutamine dose
increase from 5, 10, 20, 30, 40 and 50 mg/kg per minute
showed significant differences among the three groups (p ,
0.0004), consisting of a blunted HR response to dobut-
amine by both Chagas’ groups (Fig. 1). The difference
persisted when group 1 was compared against group 1 (p 5
0.0002) or when group 2 was compared against the control
group (p 5 0.001). In addition, the significant blunted HR
response existed even by excluding from analysis six patients
from group 2 having a biphasic contractile response, among
the three groups (p , 0.001) or between the control group
and group 2 (p , 0.003).
There were no significant differences in mean baseline
systolic and diastolic blood pressure and in systolic and
diastolic blood pressure at peak dobutamine infusion among
the three groups (Table 2).
Qualitative analysis of LV wall motion. Although sub-
jects from the control group and patients from group 1
showed uniform increase in wall motion pattern after
dobutamine, the contractile response of group 2 was com-
plex. Analysis of 224 LV segments in these 14 (group 2)
patients at a low-dose dobutamine (5 or 10 mg/kg per
minute) demonstrated no change in the extent of motion in
175 segments, improved function of 46 segments and
worsening function of 3 segments. At peak dobutamine
infusion, the function of 75 LV segments remained un-
changed, while 130 segments improved and 19 segments
worsened.
Of interest, 16 of these 19 LV wall segments that were
characterized by worsening in function exhibited a biphasic
response (18) denoted by improved wall thickening and
endocardial motion during low-dose dobutamine dose with
deterioration at peak dose. This biphasic response to do-
butamine infusion occurred at the midposterior or postero-
inferior wall segments in five patients, and at the api-
coanterolateral wall in one patient. Patients exhibiting a
biphasic response had a significant decrease in mean score
wall motion index from a baseline value of 2.13 6 0.20 to
Table 2. Hemodynamics, Echocardiographic Left Ventricular Areas and Fractional Areas
Changes Before and at Peak Dobutamine Dose
Control
(n 5 10)
Group 1
(n 5 12)
Group 2
(n 5 14) p Value
Dobutamine peak dose,
mg/kg per minute 35.0 6 5.3 42.5 6 9.7 36.4 6 11.5 0.072
HR, beats/min
Baseline 69 6 6 64 6 9 62 6 10 0.442
Dobutamine 137 6 3 130 6 13 102 6 23 , 0.0001
Maximum predicted, % 84 6 5 74 6 7 61 6 14 0.002
Blood pressure, mm Hg
Baseline
Systolic 134 6 17 124 6 12 127 6 16 0.551
Diastolic 74 6 7 71 6 12 79 6 10 0.232
Dobutamine
Systolic 141 6 10 145 6 13 140 6 18 0.272
Diastolic 62 6 9 68 6 9 75 6 6 0.381
LV area, cm2
End diastolic
Baseline 22.8 6 4.4 30.7 6 5.4 40.4 6 9.1 0.050
Dobutamine 17.4 6 4.0 25.1 6 5.1 36.6 6 9.2 0.023
End systolic
Baseline 9.9 6 2.6 16.2 6 3.2 28.5 6 9.0 0.0001
Dobutamine 5.8 6 1.2 11.4 6 3.3 24.3 6 9.7 , 0.0001
Fractional area change, %
Baseline 57.0 6 5.0 47.2 6 4.8 30.4 6 9.8 0.021
Dobutamine 66.7 6 2.5 54.7 6 6.6 35.1 6 12.2 , 0.0001
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1.86 6 0.20 at low-dose dobutamine (p 5 0.03), increasing
not significantly to 2.05 6 0.19 at peak dobutamine (p 5
0.10). The abnormal apical segments (i.e., akinetic or
aneurysmal) remained unchanged throughout.
Quantitative analysis of LV cavity areas. Significant dif-
ferences existed either at baseline and at peak dobutamine
dose in LV mean EDA, ESA, and in fractional area change
percent among the three groups (Table 2, Fig. 2). The
Chagas’ group 2 had larger LV areas and decreased frac-
tional area change percent. As a result of dobutamine
infusion, a significant decrease in mean LV ESA and an
increase in fractional area change percent occurred in the
control group but not in groups 1 and 2 (Tables 2 and 3).
Thus, although group 1 Chagas’ patients had no overt
heart disease, they had a significantly reduced fractional area
change percent at peak dobutamine infusion (p 5 0.006) as
compared with responses of the control group (Fig. 2, C).
Dobutamine side effects and ventricular arrhythmias.
Besides awareness of heart beating, the procedure was well
tolerated in most subjects. Premature ventricular contrac-
tions were present at baseline in none of group 1 and in
seven group 2 patients (50%). These were uniform in six,
bigeminy in two, and transient idioventricular rhythm in
one. During the dobutamine infusion, 17% of group 1
patients had occasional premature ventricular contractions
at doses of $40 mg/kg per minute. Two patients in group 2
had occasional ventricular triplets at dobutamine doses of 20
and 30 mg/kg per minute, and one patient had a single
6-beat run of ventricular tachycardia at a peak dose of
50 mg/kg per minute. There were no ECG ST or T wave
changes as a result of the dobutamine infusion. One patient
experienced transient asymptomatic hypotension at the end
of the test. No patient developed angina or heart failure.
Reasons for test interruption. No patient with Chagas’
disease reached his or her respective target HR. The test was
stopped in 21 of 26 (81%) Chagas’ patients because a
maximum dobutamine dose of $40 mg/kg per minute was
achieved. Six patients had biphasic responses that occurred
at dobutamine doses of 40 mg/kg per minute in three, at
30 mg/kg per minute in one, and at 20 mg/kg per minute in
two.
Clinical follow-up. Mean follow-up of all Chagas’ subjects
until December 1997 (30 6 14 months; range, 1 to 50)
yielded six cardiovascular events in group 2 patients: three
fatal (sudden death) and three nonfatal (syncope, peripheral
embolism and heart failure due to atrial fibrillation). Sig-
nificant variables predictable of adverse events included the
following: increase in HR at peak dobutamine dose of only
#35 beats/min (p 5 0.0001), attaining of age-corrected
maximum of HR of only #60% (p 5 0.0056), basal
fractional area change #40% (p 5 0.0147) and presence of
aneurysm (p 5 0.02). Variables such as age $50 years, male
sex, basal or peak dobutamine wall motion score indexes,
fractional area change percent at peak dobutamine and
ischemic or biphasic responses were nonsignificant. The
most significant Cox model for event prediction was the
combination of increase in HR at peak dobutamine dose of
only #35 beats/min and a basal fractional area change of
#40% (p 5 0.00052). Event-free survival at 29 months was
75% for all subjects with Chagas’ disease.
DISCUSSION
Results of this study demonstrate that patients with chronic
Chagas’ heart disease exhibit chronotropic incompetence
and a blunted contractile response to dobutamine stimula-
tion, even among patients (group 1) having only abnormal
Figure 1. Mean HR (6 SD) responses to stepwise dobutamine infusion in the control group, and in Chagas’ group 1 (abnormal serologic
results only with normal wall motion at baseline) and 2 (baseline wall motion abnormalities) patients. For definition of groups see
“Methods” section.
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serologic findings without overt heart disease and with
normal LV wall motion at baseline. Furthermore, patients
with LV apical wall motion abnormalities (group 2) fre-
quently exhibit a biphasic response to dobutamine consis-
tent with viable but eventually ischemic myocardium (main-
ly in the posteroinferior walls) despite normal coronary
anatomy by angiography in all patients in whom it was
performed. The possible mechanisms mediating this abnor-
mal biphasic response to dobutamine (19) are complex and
may include induced myocardial ischemia (6), beta-
adrenoreceptor dysfunction (12,13,20,21) and variable ex-
tent of structural myocardial damage (i.e., increased collagen
content) due to Chagas’ heart disease (22).
Limited inotropic reserve. As compared with control sub-
jects, in whom peak dose dobutamine was accompanied by
fractional area change up to 67%, Chagas’ group 1 patients
exhibited a significantly blunted fractional area change
response to only about 50%, similar to that previously
observed in patients with coronary artery disease and base-
line wall motion abnormalities or those developing an
ischemic response to dobutamine (23). In group 2 Chagas’
patients, the inotropic reserve was even more blunted
reaching fractional area change values approximately 30% at
peak dobutamine infusion.
The hypothesis of presumed myocardial ischemia in
chronic Chagas’ heart disease is based clinically on sugges-
tive ECG changes (3), on symptoms including acute myo-
cardial infarction with normal coronary arteries (24), on a
high proportion of segmental wall motion abnormalities
(4,5) and on experimental data derived from tissue cultures
(25,26) and living animals (6,9). As dobutamine echocardi-
ography may unmask viable ischemic myocardium (17),
results of dobutamine infusion in Chagas’ patients should
help to elucidate the pathophysiology of the responses and
assist with management strategies.
Results of this study are consistent with the hypothesis
that patients with chronic Chagas’ disease are afflicted with
impaired coronary microcirculatory reserve (6–8), as they
exhibited normal coronary arteries by angiography. We have
demonstrated previously that patients with chronic Chagas’
Figure 2. (A) Left ventricular end-diastolic areas at baseline and at
peak dobutamine infusion. (B) Left ventricular end-systolic area at
baseline and at peak dobutamine infusion. (C) Left ventricular
fractional area change (percent) at baseline and at peak dobutamine
infusion.
Table 3. Comparison Between Control Group vs Chagas’
Groups of Left Ventricular Areas and Fractional Areas Changes
at Baseline and at Peak Dobutamine Dose
Control Group vs
Group 1 Group 2
p Value
Baseline
End diastolic 0.561 0.034
End systolic 0.557 , 0.001
Fractional area change 0.90 0.043
Dobutamine
End diastolic 0.463 0.017
End systolic 0.006 , 0.001
Fractional area change 0.006 , 0.001
EDA and ESA 5 mean left ventricular end-diastolic and end-systolic areas; FAC 5
denotes fractional area change.
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heart disease may exhibit an abnormal endothelium-
dependent coronary vasoreactivity (11). An intracoronary
infusion of acetylcholine induced a paradoxic decrease in
coronary blood flow and a significantly blunted coronary
vasodilator response to adenosine. The contribution of other
endothelium-derived constrictive factors observed experi-
mentally should also be considered (9,26). Recently, in-
creased endothelin (ET-1) release from Trypanosoma cruzi-
infected human umbilical vein endothelial cells (26) has
been reported.
In addition, uniform ultrastructural alterations in myo-
cardium are observed even in chagasic asymptomatic indi-
viduals that may also contribute to abnormalities in con-
tractile function (22). These pathologic findings include
mitochondrial, nuclear, cell membrane irregularities, and
dilatation and filling of the T-tubule system with a
glycoprotein-like substance.
Chronotropic incompetence. Both Chagas’ groups were
unable to increase HR in response to high doses of dobut-
amine. Autoantibodies against both beta-adrenergic recep-
tor subtypes (beta1 and beta2) have been detected in human
chagasic sera (12,13,21). Because the cardiac chronotropic
effect of dobutamine is mainly due to its beta1 adrenorecep-
tor stimulation, recent studies suggest an interaction be-
tween antibodies to T cruzi and the receptors. Antibodies
detected in sera from chagasic patients showed molecular
mimicry recognizing both the second extracellular loop of
the human beta1 adrenergic receptor and the carboxyl-
terminal part of the ribosomal PO protein of T cruzi (13).
These antibodies have been shown to exert a positive
chronotropic effect in experiments in vitro in cardiomyocites
from neonatal rats. More recently it has been shown that
IgG fractions of sera from patients with chronic Chagas’
disease are able to decrease the HR of isolated rabbit hearts
(27). A possible role of chagasic autoantibodies in our series
is only speculative as we did not estimate its presence.
Clinically, patients with Chagas’ disease have been shown to
exhibit impaired chronotropic response during dynamic
exercise (28,29). Our observations of a blunted chronotro-
phic response to dobutamine are consistent with reduced
beta-adrenoreceptor sensitivity or down-regulation, as seen
in other dilated cardiomyopathies.
Safety. Ventricular ectopic activity before and during do-
butamine infusion was common in patients with segmental
wall motion abnormalities. Only 2 of 26 patients develop
additional arrhythmias at dobutamine doses of $30 mg/kg
per minute. Thus, this dose seems to be safe in this patient
population while allowing detection of most of the segmen-
tal wall motion abnormalities found. As no patient experi-
enced angina pectoris or showed additional ECG changes,
these signs were not useful in this patient population as
markers to stop the test.
Clinical significance. A blunted cardiac response to adren-
ergic stimulation in Chagas’ disease supports a role for
dysfunctional sympathetic activity in these patients. Re-
sponses to dobutamine infusion in conjunction with echo-
cardiography, differentiating viable from irreversibly injured
myocardial tissue, may improve the classification of these
patients for the purpose of better defined prognosis and
management.
Limitations. The finding of a limited chronotropic re-
sponse at peak dobutamine and decreased basal fractional
area change #40% as a predictor of outcome in patients
with chronic Chagas’ disease should be tested in a larger
study. We assessed LV area changes only from the two-
chamber apical view where commonly the extent of the
apical aneurysm is displayed more extensively. It may be
possible that analysis of other views might lead to different
estimations of LV area changes. Nevertheless, global con-
tractility was evaluated semiquantitatively by the score
system. We intended, but were unable to perform coronary
angiography in all patients, including group 1 patients in
whom it was not justified as these patients were mostly
asymptomatic. Finally, we cannot assume that our observa-
tions are applicable to Chagas’ patients in whom the disease
is far advanced.
Conclusions. Patients with early stages of Chagas’ disease
(only serologic evidence of Chagas’ disease but without
segmental LV dysfunction; group 1) as well as those with
baseline LV segmental wall motion abnormalities exhibit
blunted myocardial contractile response to dobutamine
infusion, chronotropic incompetence and a biphasic inotrop-
ic response (i.e., similar to that seen in ischemic myocar-
dium) to dobutamine despite normal angiographic appear-
ance of the coronary arteries.
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